Episode Summary
Executive Summary: Peter and David discuss why longevity therapies remain slow to reach patients, balancing scientific caution, FDA barriers, and the need for faster access to promising treatments. They highlight existing drugs, emerging NAD boosters and eye reprogramming, the potential for extreme lifespan extension, and a $101M XPRIZE aimed at reversing biological age while improving healthspan, cognition, muscle, skin, and immunity.
Main Topics: Why longevity therapies take so long: Both speakers explain that drug development is slow and expensive because safety and efficacy standards are high, and regulators are appropriately cautious after past harms in gene therapy and other fields. Current and emerging anti-aging interventions: David points to existing drugs like metformin and rapamycin, plus near-term developments such as NAD boosters in phase two and eye reprogramming that could enter human trials soon. FDA, regulation, and access to experimental therapies: The conversation contrasts regulatory conservatism with calls for faster pathways, including ideas for accredited/approved patient access to experimental interventions under physician oversight. Personal experimentation and self-trust in longevity medicine: Both speakers frame themselves as early adopters and self-experimenters who want firsthand experience before recommending interventions, while also emphasizing caution and transparency. Kicking the can down the road vs. immortality: The hosts debate whether longevity science is about indefinite life extension or simply extending healthy life. Peter is optimistic about major gains from AI and future tech; David doubts immortality but sees 150 as plausible. Age Reversal XPRIZE and the future of rejuvenation: Peter describes a $101 million prize co-led with David and George Church to incentivize measurable biological age reversal in less than a year, with a focus on multiple tissues and organs. Personal fulfillment and resilience: David answers a listener question about happiness, describing fulfillment from meaningful work, resilience against criticism, and the challenges of parenting teenagers.
Key Arguments: Meaningful longevity therapies are slow because drug development is difficult, costly, and heavily regulated, not because progress is absent. Some interventions already show promise, including metformin and rapamycin, which David believes can slow aspects of aging. Aging should be treated as a medical condition if society wants more investment, clearer regulatory pathways, and faster translation to patients. A more flexible access model for experimental therapies could help terminal or high-risk patients try promising treatments under supervision. Peter argues the FDA is structurally biased toward avoiding harm from approval rather than weighing the cost of delayed access. Both speakers think self-experimentation can be valuable if done transparently and with a willingness to publicize negative results. The goal is not necessarily immortality, but substantially extended healthy lifespan and better function later in life. A large prize can accelerate innovation by concentrating talent on a measurable challenge, similar to prior XPRIZE programs.
Data Points: Time since David's podcast pause: Since February - He said he has not released a podcast because he is writing a second book and editing a paper. Development stage of Metro Biotech work: Phase two studies - David said NAD booster drugs for diseases of aging are in phase two and may be 2–3 years from possible availability. Estimated timeline for some eye reprogramming work: As soon as next year - David said eye reprogramming to cure blindness could move into humans next year. Drug development cost: $400–500 million - Peter cited the cost of developing a drug that can still fail despite huge spending. Stem cell reduction with age: 100x to 1000x more in youth - Peter described how stem cell populations decline across tissues as people age. Potential lifespan target: 150 years - David said 150 is achievable in many lifespans, though not immortality. Singularity timing: Early 2040s - Peter referenced Ray Kurzweil’s estimate for a technological inflection point. Age reversal prize amount: $101 million - Peter described the XPRIZE focused on age reversal. Target biological age reversal: 20 years or more - The proposed prize asks for therapies that reverse biological age by at least 20 years. Treatment duration requirement: Less than a year - Prize rules being discussed require the therapy's effect to last under a year while still demonstrating reversal. Economic value of one healthy year: $86 trillion - David cited this as the long-run U.S. economic impact of adding one healthy year of life. Number of FDA-approved drugs: 3,000 - Used to illustrate repurposing opportunities for existing medicines. Number of diseases: 12,000 - Used to argue many conditions may be treatable with already-approved drugs.
Pivotal Quotes: "We are kicking the can down the road, but that's the point. Life is wonderful, and the more times we kick the can down the road, the more life and wonder we have." — Peter: On whether longevity science is merely delaying death or meaningfully extending life. "If we can show that aging is slowable with a treatment, that they would strongly consider approving that medicine for the treatment of aging." — David: On how the FDA may eventually accept aging as a treatable condition. "The goal is to inspire companies and labs, individuals to work on methods to safely reverse aging in multiple tissues and organs to rejuvenate the body and make it function better." — David: On the purpose of the Age Reversal XPRIZE.
Implications: Listeners should expect slow but real progress: some therapies are already in use, more are nearing trials, and regulatory reform could accelerate access. The field is shifting from lifespan to healthspan, with major economic and scientific incentives to make rejuvenation measurable.